Eloralintide: Amylin agonist!

Hong Kong Yanpep International
Good news, everyone! The full sequence of Eloralintide is in the paper, so I'm guessing research peptides will be available relatively soon.
 
Haha, how many people on this forum are already thinking about when Eloralintide will show up on the, uh, 'alternative' market after seeing these early results?

I actually have some cagrilintide that I got early on, thinking it might be useful if I hit a plateau. Now it sounds like it could be out of date before I even needed it...
 
Thanks for sharing this! I'm super excited about Eloralintide. I'm currently using Tirz and Reta for maintenance. I tried Cagri, but it gave me a constant headache that only stopped when I discontinued it. I think Eloralintide combined with Reta would be amazing, and I'm betting maintenance would only require a small dose of each. I'm really looking forward to trying it out.
 
I will absolutely, without a doubt, switch my, uh, "research project" over to Elora from Cagri the moment it becomes available.
 
I wonder how much this will cost. I know cagri can be pretty pricey, so this one will probably be even more.
 
Cagrilintide won't become obsolete. It's still a long-acting amylin that boosts satiety and assists with weight loss. Tylenol isn't obsolete just because Aleve exists. Just like Jiffy isn't obsolete because Skippy exists.

Unless there's a fibril/oligomer issue, then it might be a different story. Elora sounds like a cool name for an oligomer queen in a kid's movie, though.
 
Elora seems like it'll be stronger and cause fewer side effects. But cagri is effective at controlling appetite, so you should still consider using it in combination with tirz/sema/reta if necessary.
 
Mike_1977 said:
I wonder how much this will cost. I know cagri can be pretty pricey, so this one will probably be even more.

Yeah, the cost is always a concern. I saw an article talking about how the actual cost to manufacture some of these GLP-1 meds can be surprisingly low. I hope that translates into more affordable options eventually.
 
HalfSizeMe said:
Thanks for sharing this! I'm super excited about Eloralintide. I'm currently using Tirz and Reta for maintenance. I tried Cagri, but it gave me a constant headache that only stopped when I discontinued it. I think Eloralintide combined with Reta would be amazing, and I'm betting maintenance would only require a small dose of each. I'm really looking forward to trying it out.

Just be careful and monitor your body. I saw an article about the side effects of these meds. It's important to be aware of the risks. Some people experience severe nausea or constipation, so watch for the early warning signs and stop if it gets too bad.
 
Sage_1999 said:
Elora seems like it'll be stronger and cause fewer side effects. But cagri is effective at controlling appetite, so you should still consider using it in combination with tirz/sema/reta if necessary.

I agree with Sage_1999, don't ditch the cagri too fast. I get good results with it. Plus, stacking peptides can sometimes lead to unexpected results, so start low and go slow!
 
I'm just hoping Elora doesn't have the same side effect profile as some of the others. I've heard some horror stories.
 
The calcitonin receptor selectivity distinction is the key pharmacological difference - cagri's broader receptor activity beyond amylin 1/3 is part of why the clinical profiles diverge. The 10% vs 20% weight loss gap at one year is substantial and likely reflects that receptor specificity translating into a cleaner satiety signal. Eloralintide's specificity advantage may also mean a narrower side effect profile since you're not getting calcitonin receptor-mediated effects that aren't targeted.
 
Phase 1 data is always the exciting part before the reality of larger trials sets in. If the amylin pathway works as well as reta for some people, having a longer-acting option in that class is worth watching. What's the timeline looking like for further trials?
 
There's a compound in early trials right now, a selective, long-acting hormone-pathway agonist being tested for obesity treatment, dosed once weekly by injection. Its active period in the body runs somewhere around two weeks based on published research, not just a random guess from an app. Honestly surprised the app actually got it right.
 
Been wondering the same thing. If the whole benefit of this newer compound category came down to appetite suppression alone, why would this one specifically generate so much excitement? A different existing medication already suppresses appetite significantly, so that alone wouldn't be a reason to switch.

From what's been read though, this category may do more than just curb hunger. The signaling pathway involved interacts with central pathways tied to a hormone called leptin, and animal research suggests it might partially restore how responsive the brain is to that hormone.

People dealing with typical excess weight usually have plenty of that hormone circulating, since fat tissue produces it. The issue seems to be reduced brain sensitivity to what that hormone communicates about the body's long-run energy reserves.

In theory, that means this category might influence how the body actually defends its weight overall, not just hunger levels moment to moment. Loosely tied to the idea of a body weight set point, though that theory itself remains debated.

Way too soon to say this specific compound actually resets anyone's baseline, or that its human results trace back in any real way to better hormone sensitivity. Still, that angle is exactly what keeps this genuinely interesting.
 
Back
Top